Loading...
SIGHT
XPAR
Market cap20mUSD
Nov 20, Last price  
0.08EUR
1D
-1.45%
1Q
-34.67%
Jan 2017
-99.03%
IPO
-99.11%
Name

Gensight Biologics SA

Chart & performance

D1W1MN
XPAR:SIGHT chart
P/E
—
P/S
18,466.30
EPS
—
Vol. 1Y
72.53%
Shs. 5Y
33.38%
Rev. 5Y
-81.32%
Div Yld LY
—
Div Yld TTM
—
Revenues
1k
-99.96%
908,4421,102,6933,559,9983,001,0003,702,0004,346,000700,0004,394,0005,276,0002,582,0001,267,0002,625,0001,000
Net income
-12m
L-14.03%
-2,762,861-6,671,142-13,653,620-22,081,663-24,112,000-33,453,000-30,710,000-34,016,000-28,617,000-27,624,000-26,220,000-14,001,000-12,036,000
CFO
-9m
L-27.51%
-1,950,097-5,516,392-12,094,554-19,641,790-18,782,000-28,383,000-28,112,000-15,044,000-17,139,000-33,753,000-24,663,000-12,937,000-9,378,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Key people

Chairman of the Board · since 2024
Connie Cepko
Founder
Serge Picaud
Founder
Botond Roska
Founder
Jose-Alain Sahel
Founder, Director
Jan Umiastowski
Chief Financial Officer · since 2024
Julio Benedicto
Senior Vice President - Strategy and Operations · since 2024
Scott Jeffers
Chief Technology Officer · since 2022
Magali Gibou
Vice President - Regulatory and Quality · since 2023
Magali Taiel
Chief Medical Officer · since 2019
Cedric Moreau
Director, Representative of Sofinnova Partners · since 2019
Laurence Rodriguez
Chief Executive Officer, Director · since 2024
Independent Director · since 2020
Francoise de Craecker
Independent Director · since 2021
Maritza Mcintyre
Independent Director · since 2019
William Monteith
Independent Director · since 2024
Simone Seiter
Independent Director · since 2017
IPO date
Jul 13, 2016
Employees
45
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
74 RUE DU FBG ST ANTOINE
PARIS 12 75012
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT